Monoclonal antibody therapy for COVID-19 – Part 1

COVID-19 vaccines have dominated the headlines. Not garnering the same attention, but just as important, is last November’s US Food and Drug Administration Emergency Use Authorization (EUA) allowing monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19.

 

This episode, beginning a three-part series on this treatment option, will address questions and concerns about the administration of monoclonal antibody therapy.

 

Guest speaker:

Stacy Lauderdale, PharmD

Senior Director

Drug Information

Vizient

 

Moderator:

Tomas Villanueva, DO, MBA, FACPE, SFHM

Associate Vice President

Clinical Resources

Vizient

 

Show Notes:

[01:05] Science behind the treatment

[02:09] Evidence is compelling but hypothesis-generating

[03:43] Choosing an option

[04:37] Role of COVID testing

[04:52] Inclusion and exclusion factors

[06:17] Risk of anaphylaxis

[06:54] Social determinants for treatment

[07:44] Patient risk factors

 

Links | Resources:

Press release and information from FDA Click here

Information from FDA on EUA for monoclonal antibody therapy Click here

ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here

[ For more information, contact: ASPRstakeholder@HHS.gov ]

JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here

 

Subscribe Today!

Apple Podcasts

Spotify

Android

Google Podcasts

Stitcher

RSS Feed